Disorders of metal metabolism: Wilson and Menkes disease — branching viva

Opening framework

My framework rests on a single unifying concept. Wilson disease and Menkes disease are both disorders of the copper-transporting ATPase, a membrane pump that moves copper across a biological barrier. ATP7B sits in the hepatocyte and excretes copper into bile; when it fails, copper accumulates (toxicity) and poisons the liver, basal ganglia and cornea. ATP7A sits in the gut enterocyte and the blood-brain barrier and ferries dietary copper into the body; when it fails, copper is trapped in the enterocyte and the body is starved (deficiency). Same ion, same protein family, the opposite clinical problem - and the treatment follows the direction: remove copper in Wilson, replace copper in Menkes. [1] [5]

The integrated copper panel and the Leipzig score

The Wilson panel is interpreted as a whole because no single test suffices. Ceruloplasmin is low under 0.2 grams per litre in the majority, but it is an acute-phase reactant and is normal in 10 to 15 percent of cases, particularly hepatic presentations. The 24-hour urinary copper is the most useful single test, elevated above 0.6 to 1 micromole per 24 hours and markedly elevated in acute failure. The slit-lamp examination finds Kayser-Fleischer rings, and the hepatic copper on biopsy is the gold standard above 250 micrograms per gram dry weight. Molecular testing of ATP7B confirms the diagnosis and enables family screening. [1] [3]

The Leipzig score, from Ferenci and colleagues, integrates ceruloplasmin, hepatic copper, urinary copper, neurological features, Kayser-Fleischer rings and ATP7B variants into a validated diagnostic instrument, and a high score confirms Wilson disease without liver biopsy in typical cases. The caveat the examiner probes is the normal ceruloplasmin: it does not exclude the diagnosis, and that is why the score integrates the whole panel. [2]

The three therapeutic pillars and the trientine preference

The management of Wilson disease rests on three pillars. Chelation with penicillamine or trientine binds copper for urinary excretion and is the foundation of symptomatic therapy. Zinc acts by a different mechanism: it induces metallothionein in the enterocyte, which binds dietary copper and prevents its absorption, and it is used for maintenance, for pre-symptomatic siblings, and in pregnancy. Liver transplantation is curative because the donor liver carries a normal ATP7B gene, and it is indicated for acute Wilsonian failure, decompensated cirrhosis unresponsive to therapy, and selected refractory neurological disease. [1] [9]

I prefer trientine over penicillamine for initial therapy in a neurologically presenting patient because penicillamine can cause an initial worsening of neurological symptoms by mobilising copper from tissue stores into the circulation, and trientine has a better side-effect profile. The patient is monitored with serial 24-hour urinary copper to confirm adequacy, and treatment is lifelong - non-adherence is the greatest threat to survival. [3]

Branch: the acute Wilsonian crisis

If a patient on chelation withdraws therapy and presents in acute liver failure with a Coombs-negative haemolytic anaemia and acute kidney injury, that is the acute Wilsonian crisis, and it is a transplant emergency. The free non-ceruloplasmin copper floods the circulation, lyses red cells, and causes hepatic necrosis with near-100 percent mortality without transplantation. I begin copper removal immediately - chelation plus plasma exchange or haemofiltration or albumin dialysis as a bridge - and list the patient urgently for liver transplantation, arranging transfer to a transplant centre. The bridge keeps the patient alive to transplant; the transplant is the cure. [9] [1]

Branch: the infant with Menkes disease

When the examiner switches to the 3-month-old boy with hypotonia, seizures, kinky hair and low serum copper, the framework is the same unifying concept in reverse. ATP7A is lost, copper is trapped in the enterocyte, and the body and brain are functionally copper-deficient. Each clinical feature maps to a copper-dependent enzyme failure: lysyl oxidase failure weakens elastin, producing arterial tortuosity, bladder diverticula and loose skin; dopamine-beta-hydroxylase failure disrupts catecholamines, producing hypothermia and autonomic instability; tyrosinase failure depigments the hair and skin; and cytochrome c oxidase failure cripples oxidative phosphorylation in the brain, driving the seizures and neurodegeneration. [5]

The treatment is subcutaneous copper histidinate, which bypasses the enterocyte block. Oral copper is useless because it simply adds to the copper already trapped. The Kaler neonatal study showed that the benefit is greatest when treatment begins in the first month of life, which is why early or prenatal diagnosis in an at-risk family is so important - though the benefit is limited in patients with null ATP7A variants. [4]

Closing: the counselling fork and the honest prognosis

The counselling fork between the two diseases is the closing point. Wilson disease is autosomal recessive, so I screen siblings biochemically and molecularly and start an affected pre-symptomatic sibling on zinc or chelation to prevent the disease from ever declaring itself - one of the most effective interventions in inherited metabolic medicine. Menkes disease is X-linked, so I counsel the carrier mother: each male pregnancy carries a 50 percent recurrence risk, and I offer prenatal or preimplantation genetic diagnosis. The honest closing statement is that Wilson disease is treatable and, with faithful adherence or transplantation, curable, while Menkes disease, even with early copper histidinate, remains a severe neurodegenerative disease with a guarded prognosis - and the gene-therapy frontier is the leading translational hope. [1] [5]